Central Nervous System Metastases
11
0
2
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
18.2%
2 terminated out of 11 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Predictive Factors for CNS Metastases in Early Breast Cancer Using Liquid Biopsy (AKRA CŽS)
Whole Brain Radiation Using IMRT for Patients With Brain Metastases
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Focal Intraoperative Radiotherapy of Brain Metastases
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
Sunitinib in Treating Young Patients With Refractory Solid Tumors
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases